- ►ajcn.org PB Higgins, JR Fernandez, WT Garvey, WM … - American Journal of Clinical Nutrition, 2008 - Am Soc Nutrition 3 Supported by grants from the National Institutes of Health (R01-DK067426,
P30-DK56336, and M01-RR-00032) and the American Heart Association (0515149B).
PBH was supported in part by a predoctoral fellowship from the American ... Cited by 1 - Related articles - All 4 versions
Q Cheng, PK Law, M de Gasparo, PS Leung - Journal of Pharmacology and Experimental …, 2008 - ASPET LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] is an
inhibitor of dipeptidyl peptidase IV that delays the degradation of
glucagon-like peptide-1 (GLP-1). Valsartan [N-(1-oxopentyl)-N-[[2'-(1H- ... Related articles - All 2 versions
S Kalra, B Kalra, A Kumar - Recent Patents on Endocrine, Metabolic &# 38; …, 2009 - ingentaconnect.com Received: February 5, 2009; Accepted: February 26, 2009; Revised: March 17, 2009
Abstract: Much interest has focused on the newer incretin-based therapeutic
modalities for diabetes, especially GLP-1 analogues. While the ... Related articles